Technical charts show that shares of Infosys, ICICI Bank, Dr. Reddy's, Eicher Motors and Shriram Finance can potentially rally up to 15% from here on as Nifty attempts a pullback towards its 100-DMA.
DIIs have doubled their shareholding, in terms of absolute number of shares held, in 46 out of the Nifty 500 companies in the last nine months, shows ACE equity data.
Here's a technical outlook on 5 largecap stocks post Q3 results. Charts hint towards a positive bias for Bajaj Finance and Bajaj Auto; whereas a likely fall for Maruti, Tata Motors and Dr. Reddy's.
Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals after analysts remained cautious on the company's Q3 performance
Dr Reddy's Laboratories reported its consolidated Q3 results with a 2.5 per cent rise in profit to Rs 1,413.3 crore compared to Rs 1,378.9 crore in the same period last year
Earlier in the day, the generic drugmaker reported consolidated net profit of Rs 1,414 crore ($163.7 million) for the quarter ended Dec. 31
The growth was largely driven by revenue from its recently acquired nicotine replacement therapy (NRT) portfolio and performance in the European and emerging markets
Dr Reddy's Lab Q3 results: Shares of Dr Reddy's closed at Rs 1,289.35 on Thursday ahead of its results
Q3FY25 company results, January 23: Two Adani entities including Adani Energy Solutions and Adani Green Energy will release results for the Oct-Dec quarter today
Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025
Q3 FY25 company results January 20: Zomato, Paytm, IDBI Bank, L&T Finance, Dr Reddy's, and YES Bank will be releasing their Oct-Dec quarter report today
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'
Thus far in the month of December, Dr Reddy's share price has rallied 15%, its biggest monthly rally since September 2020, when it had surged 22%
At 02:37 pm; Nifty Pharma, the sole gainer among sectoral indices, was up 1.8 per cent, as compared to 1 per cent decline in the Nifty 50.
The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'
Dr Reddy's Laboratories on Thursday said Kazakhstan revenue authority has levied a penalty of Rs 28.7 lakh on its subsidiary. The Department of State Revenue, Bostandyk district of Almaty, Kazakhstan has imposed the penalty on Dr Reddy's Laboratories Kazakhstan LLP towards disallowance of claim of certain expenses by the tax authorities for the calendar year 2021, the drug firm said in a regulatory filing. The order levies a penalty of KZT 17,597,212 (Rs 2.87 million), it added. "Based on our evaluation, there is no material impact on the financials, operations, or other activities of the company," the Hyderabad-based drug firm said.
In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for Toripalimab
In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab
Dr Reddy's Laboratories share price fell up to 3.2 per cent at Rs 1,175 per share on the BSE in Thursday's
Dr Reddy's Laboratories Ltd on Tuesday said the US health regulator has issued a Form 483 with seven observations to its active pharmaceutical ingredient manufacturing facility in Bollaram, Hyderabad. "The US Food & Drug Administration (USFDA) today completed a GMP inspection at our API manufacturing facility (CTO-2) in Bollaram, Hyderabad," Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing. The inspection was conducted from November 13-19, 2024, it added. "We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline," the company said. As per US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.